14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tildrakizumab is a high-affinity, humanised, IgG1 κ antibody targeting interleukin 23 p19 that represents an evolving treatment strategy in chronic plaque psoriasis. Previous research suggested clinical improvement with inhibition of interleukin 23 p19. We did two phase 3 trials to investigate whether tildrakizumab is superior to placebo and etanercept in the treatment of chronic plaque psoriasis.

          Related collections

          Author and article information

          Journal
          Lancet
          Lancet (London, England)
          Elsevier BV
          1474-547X
          0140-6736
          July 15 2017
          : 390
          : 10091
          Affiliations
          [1 ] SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany. Electronic address: kreich@dermatologikum.de.
          [2 ] Probity Medical Research, Waterloo, ON, Canada.
          [3 ] Oregon Medical Research Center, Portland, OR, USA.
          [4 ] Department of Dermatology, University of Texas Health Science Center, Houston, TX, USA.
          [5 ] Epworth Hospital Department of Dermatology, University of Melbourne, Melbourne, VIC, Australia.
          [6 ] Comprehensive Center for Inflammation Medicine, University Medical School Schleswig-Holstein, University of Lübeck, Lübeck, Germany.
          [7 ] Merck & Co, Kenilworth, NJ, USA.
          [8 ] Harvard Medical School, Boston, MA, USA.
          Article
          S0140-6736(17)31279-5
          10.1016/S0140-6736(17)31279-5
          28596043
          9a859fe3-a739-4d30-b022-149826920566
          History

          Comments

          Comment on this article